You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Alnylam stock poised to climb, reports say

John Maraganore is chief executive of Cambridge-based Alnylam.

Bloomberg News/File 2007

John Maraganore is chief executive of Cambridge-based Alnylam.

Continue reading below

Alnylam Pharmaceuticals Inc., which describes itself as a leading RNAi therapeutics company, had its price objective raised by Needham & Co. to $40 from $28 in a research report released this week, Analyst Ratings Network reported. The firm has a “buy” rating on the stock. Piper Jaffray recently raised its price target to $42.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of